NVCR Novocure
- 21.050
- +0.730+3.59%
- 21.000
- -0.050-0.24%
Novocure News
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
The component stock Novavax Pharmaceuticals closed up 47.64%, continuing its 98.66% increase on Friday (May 10); AC Immune rose 42.86%, MacroGenics rose 32.33% Humacyte, Prime Medicine, Beam, Twist Bioscience, Recursion Pharmaceuticals, Coherus BioScience
The component stock Novavax Pharmaceuticals closed up 47.64%, continuing its 98.66% increase on Friday (May 10); AC Immune rose 42.86%, MacroGenics rose 32.33% Humacyte, Prime Medicine, Beam, Twist Bioscience, Recursion Pharmaceuticals, Coherus BioSciences rose 16.60%-10.00% Novocure also rose 9.17%; Zent
Unveiling 8 Analyst Insights On NovoCure
Throughout the last three months, 8 analysts have evaluated NovoCure (NASDAQ:NVCR), offering a diverse set of opinions from bullish to bearish.The following table summarizes their recent ratings, shed
Earnings Call Summary | Novocure(NVCR.US) Q1 2024 Earnings Conference
The following is a summary of the NovoCure Limited (NVCR) Q1 2024 Earnings Call Transcript:Financial Performance:NovoCure reported a net revenue of $139 million in Q1 2024, up 13% year-over-year. The
Novocure Price Target Cut to $22.00/Share From $24.00 by HC Wainwright & Co.
Novocure Price Target Cut to $22.00/Share From $24.00 by HC Wainwright & Co.
Novocure Is Maintained at Neutral by HC Wainwright & Co.
Novocure Is Maintained at Neutral by HC Wainwright & Co.
HC Wainwright & Co. Maintains Neutral on NovoCure, Lowers Price Target to $22
HC Wainwright & Co. analyst Emily Bodnar maintains NovoCure with a Neutral and lowers the price target from $24 to $22.
Analysts Offer Insights on Healthcare Companies: SELLAS Life Sciences Group (SLS) and NovoCure (NVCR)
NovoCure Ltd (NVCR) Q1 2024 Earnings: Revenue Surpasses Estimates, Narrower Net Loss Reported
Novocure Secures New $400M Non-Dilutive Debt Financing From Pharmakon
Use of proceeds to fund working capital needs stemming from Novocure's anticipated launch in non-small cell lung cancer and settle, upon maturity, Novocure's convertible notes
Novocure Expects Top-line Data From Phase 3 PANOVA-3 Clinical Trial in Locally Advanced Pancreatic Cancer in Q4
Novocure Expects Top-line Data From Phase 3 PANOVA-3 Clinical Trial in Locally Advanced Pancreatic Cancer in Q4
NovoCure Q1 2024 Adj EPS $(0.36) Beats $(0.42) Estimate, Sales $138.50M Beat $131.45M Estimate
NovoCure (NASDAQ:NVCR) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.42) by 14.29 percent. The company reported quarterly sales of $138.50 million wh
Earnings Flash (NVCR) NOVOCURE Reports Q1 Revenue $138.5M, Vs. Street Est of $131.5M
07:03 AM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (NVCR) NOVOCURE Reports Q1 Revenue $138.5M, vs. Street Est of $131.5M
Novocure 1Q Loss $38.8M >NVCR
Novocure 1Q Loss $38.8M >NVCR
Novocure Price Target Raised to $28.00/Share From $25.00 by Piper Sandler
Novocure Price Target Raised to $28.00/Share From $25.00 by Piper Sandler
Piper Sandler: Reiterates the NovoCure (NVCR.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $25.00 to $28.00.
Piper Sandler: Reiterates the NovoCure (NVCR.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $25.00 to $28.00.
Piper Sandler Reiterates Overweight on NovoCure, Raises Price Target to $28
Piper Sandler analyst Jason Bednar reiterates NovoCure with a Overweight and raises the price target from $25 to $28.
Is NovoCure (NASDAQ:NVCR) Using Debt In A Risky Way?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much
Novocure Reports 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, At AACR Annual Meeting 2024
Novocure Reports 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, At AACR Annual Meeting 2024
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Analysis
Price Target
No Data
